Monoclonal antibody U36, a suitable candidate for clinical immunotherapy of squamous-cell carcinoma, recognizes a CD44 isoform

N. L W Van Hal, G. A M S Van Dongen, E. M C Rood-Knippels, Paul Van der Valk, Gordon B. Snow, Ruud H. Brakenhoff

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

At present, tumor-targeting with monoclonal antibodies (MAbs) is among the most promising novel adjuvant-therapy modalities for the treatment of patients with minimal residual disease of head-and-neck squamous-cell carcinoma (HNSCC). For this purpose we developed MAb U36, recognizing a 200-kDa antigen expressed on the outer cell surface of squamous-cell carcinomas and their normal counterparts. Clinical radioimmunoscintigraphy (RIS) and biodistribution studies have shown that the MAb-U36-defined antigen is a suitable target molecule for antibody-based therapy of head-and-neck cancer. In the present study we further characterized the antigen by cDNA cloning. The cDNA was isolated by expression cloning in COS-7 cells. Sequence analysis and database searching revealed that the MAb-U36-defined antigen is identical to the squamous-cell-specific CD44 splice variant epican. The epitope recognized by MAb U36 was mapped by screening overlapping synthetic peptides of the epican-specific region encoded by exon 7-11 (v3-v7), and appeared to be located in the v6 domain. The applicability of MAb U36 for targeting human tumors of various origin expressing the CD44vb domain is discussed.

Original languageEnglish
Pages (from-to)520-527
Number of pages8
JournalInternational Journal of Cancer
Volume68
Issue number4
DOIs
Publication statusPublished - 21 Dec 1996

Cite this

@article{96606c222b3d426f97a71526414a614b,
title = "Monoclonal antibody U36, a suitable candidate for clinical immunotherapy of squamous-cell carcinoma, recognizes a CD44 isoform",
abstract = "At present, tumor-targeting with monoclonal antibodies (MAbs) is among the most promising novel adjuvant-therapy modalities for the treatment of patients with minimal residual disease of head-and-neck squamous-cell carcinoma (HNSCC). For this purpose we developed MAb U36, recognizing a 200-kDa antigen expressed on the outer cell surface of squamous-cell carcinomas and their normal counterparts. Clinical radioimmunoscintigraphy (RIS) and biodistribution studies have shown that the MAb-U36-defined antigen is a suitable target molecule for antibody-based therapy of head-and-neck cancer. In the present study we further characterized the antigen by cDNA cloning. The cDNA was isolated by expression cloning in COS-7 cells. Sequence analysis and database searching revealed that the MAb-U36-defined antigen is identical to the squamous-cell-specific CD44 splice variant epican. The epitope recognized by MAb U36 was mapped by screening overlapping synthetic peptides of the epican-specific region encoded by exon 7-11 (v3-v7), and appeared to be located in the v6 domain. The applicability of MAb U36 for targeting human tumors of various origin expressing the CD44vb domain is discussed.",
author = "{Van Hal}, {N. L W} and {Van Dongen}, {G. A M S} and Rood-Knippels, {E. M C} and {Van der Valk}, Paul and Snow, {Gordon B.} and Brakenhoff, {Ruud H.}",
year = "1996",
month = "12",
day = "21",
doi = "10.1002/(SICI)1097-0215(19961115)68:4<520::AID-IJC19>3.0.CO;2-8",
language = "English",
volume = "68",
pages = "520--527",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "4",

}

Monoclonal antibody U36, a suitable candidate for clinical immunotherapy of squamous-cell carcinoma, recognizes a CD44 isoform. / Van Hal, N. L W; Van Dongen, G. A M S; Rood-Knippels, E. M C; Van der Valk, Paul; Snow, Gordon B.; Brakenhoff, Ruud H.

In: International Journal of Cancer, Vol. 68, No. 4, 21.12.1996, p. 520-527.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Monoclonal antibody U36, a suitable candidate for clinical immunotherapy of squamous-cell carcinoma, recognizes a CD44 isoform

AU - Van Hal, N. L W

AU - Van Dongen, G. A M S

AU - Rood-Knippels, E. M C

AU - Van der Valk, Paul

AU - Snow, Gordon B.

AU - Brakenhoff, Ruud H.

PY - 1996/12/21

Y1 - 1996/12/21

N2 - At present, tumor-targeting with monoclonal antibodies (MAbs) is among the most promising novel adjuvant-therapy modalities for the treatment of patients with minimal residual disease of head-and-neck squamous-cell carcinoma (HNSCC). For this purpose we developed MAb U36, recognizing a 200-kDa antigen expressed on the outer cell surface of squamous-cell carcinomas and their normal counterparts. Clinical radioimmunoscintigraphy (RIS) and biodistribution studies have shown that the MAb-U36-defined antigen is a suitable target molecule for antibody-based therapy of head-and-neck cancer. In the present study we further characterized the antigen by cDNA cloning. The cDNA was isolated by expression cloning in COS-7 cells. Sequence analysis and database searching revealed that the MAb-U36-defined antigen is identical to the squamous-cell-specific CD44 splice variant epican. The epitope recognized by MAb U36 was mapped by screening overlapping synthetic peptides of the epican-specific region encoded by exon 7-11 (v3-v7), and appeared to be located in the v6 domain. The applicability of MAb U36 for targeting human tumors of various origin expressing the CD44vb domain is discussed.

AB - At present, tumor-targeting with monoclonal antibodies (MAbs) is among the most promising novel adjuvant-therapy modalities for the treatment of patients with minimal residual disease of head-and-neck squamous-cell carcinoma (HNSCC). For this purpose we developed MAb U36, recognizing a 200-kDa antigen expressed on the outer cell surface of squamous-cell carcinomas and their normal counterparts. Clinical radioimmunoscintigraphy (RIS) and biodistribution studies have shown that the MAb-U36-defined antigen is a suitable target molecule for antibody-based therapy of head-and-neck cancer. In the present study we further characterized the antigen by cDNA cloning. The cDNA was isolated by expression cloning in COS-7 cells. Sequence analysis and database searching revealed that the MAb-U36-defined antigen is identical to the squamous-cell-specific CD44 splice variant epican. The epitope recognized by MAb U36 was mapped by screening overlapping synthetic peptides of the epican-specific region encoded by exon 7-11 (v3-v7), and appeared to be located in the v6 domain. The applicability of MAb U36 for targeting human tumors of various origin expressing the CD44vb domain is discussed.

UR - http://www.scopus.com/inward/record.url?scp=0029803888&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0215(19961115)68:4<520::AID-IJC19>3.0.CO;2-8

DO - 10.1002/(SICI)1097-0215(19961115)68:4<520::AID-IJC19>3.0.CO;2-8

M3 - Article

VL - 68

SP - 520

EP - 527

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 4

ER -